| 000 | 01633 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250512211549.0 | ||
| 264 | 0 | _c19840412 | |
| 008 | 198404s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1983.1.11.701 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWolff, S N | |
| 245 | 0 | 0 |
_aHigh-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cNov 1983 |
||
| 300 |
_a701-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBlood Cell Count |
| 650 | 0 | 4 |
_aBone Marrow _xdrug effects |
| 650 | 0 | 4 | _aBone Marrow Transplantation |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPodophyllotoxin _xanalogs & derivatives |
| 700 | 1 | _aFer, M F | |
| 700 | 1 | _aMcKay, C M | |
| 700 | 1 | _aHande, K R | |
| 700 | 1 | _aHainsworth, J D | |
| 700 | 1 | _aGreco, F A | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 1 _gno. 11 _gp. 701-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1983.1.11.701 _zAvailable from publisher's website |
| 999 |
_c6366048 _d6366048 |
||